Cargando…
The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals
OBJECTIVE: This study was performed to investigate the impact of HAART versus no HAART and nucleoside free versus nucleoside containing HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV/HCV co-infected patients. In additi...
Autores principales: | Vogel, M, Ahlenstiel, G, Hintsche, B, Fenske, S, Trein, A, Lutz, T, Schürmann, D, Stephan, C, Khaykin, P, Bickel, M, Mayr, C, Baumgarten, A, Buggisch, P, Klinker, H, John, C, Gölz, J, Staszewski, S, Rockstroh, JK |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352215/ https://www.ncbi.nlm.nih.gov/pubmed/20452894 http://dx.doi.org/10.1186/2047-783X-15-3-102 |
Ejemplares similares
-
Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012) -
Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART)
por: Dold, Leona, et al.
Publicado: (2015) -
Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018) -
Clearance of HCV by Combination Therapy of Pegylated Interferon α-2a and Ribavirin Improves Insulin Resistance
por: Kim, Hong Joo, et al.
Publicado: (2009) -
Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
por: Macías, Juan, et al.
Publicado: (2015)